View in EDS HTML Full Text PDF Full Text

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.

Saved in:
Bibliographic Details
Title: Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.
Authors: Wawruszak, Anna1 (AUTHOR) anna.wawruszak@umlub.pl, Luszczki, Jarogniew2 (AUTHOR), Bartuzi, Damian3,4 (AUTHOR), Kalafut, Joanna1 (AUTHOR), Okon, Estera1 (AUTHOR), Czerwonka, Arkadiusz1 (AUTHOR), Stepulak, Andrzej1 (AUTHOR)
Source: Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2025, Vol. 40 Issue 1, p1-16. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14756366
DOI:10.1080/14756366.2025.2458554